Physician profile
Gideon Richards
NPI 1831367788
$4,149.40
in general payments reported to CMS, 2019-2025
32 companies · $48.70 in 2025
The $48.70 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,537 · 2020: $549 · 2021: $378 · 2022: $448 · 2023: $638 · 2024: $550 · 2025: $48.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,236.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neotract INC. | $1,217.76 | 2019 | |
| Uromedica, Incorporated | $413.35 | 2020-2022 | |
| Boston Scientific Corporation | $378.55 | 2019-2024 | Ams 700, Greenlight Xps |
| Coloplast Corp | $286.55 | 2020-2025 | Speedicath, Titan |
| Bayer Healthcare Pharmaceuticals INC. | $177.66 | 2021-2023 | |
| Teleflex LLC | $173.47 | 2021-2024 | Urolift |
| Endo Pharmaceuticals INC. | $153.88 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $134.20 | 2023 | Orgovyx |
| Pfizer INC. | $125.22 | 2019-2023 | |
| Olympus America INC. | $122.76 | 2022 | |
| Ambu INC. | $105.73 | 2022-2024 | |
| Astellas Pharma US INC | $84.77 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $75.89 | 2020-2023 | Lynparza |
| Janssen Biotech, INC. | $73.45 | 2019-2021 | |
| Myovant Sciences INC. | $63.86 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $61.66 | 2023 | |
| Urogen Pharma, INC. | $60.14 | 2020-2022 | |
| Blue Earth Diagnostics | $58.68 | 2019-2021 | |
| Progenics Pharmaceuticals, INC. | $58.53 | 2022-2023 | Pylarify |
| Myriad Genetic Laboratories, INC. | $49.04 | 2021 | |
| Abbvie INC. | $44.67 | 2021-2024 | |
| C. R. Bard, INC. & Subsidiaries | $41.26 | 2020 | |
| Sun Pharmaceutical Industries INC. | $28.51 | 2019-2022 | |
| Puma Biotechnology, INC. | $22.37 | 2019 | |
| Novartis Pharmaceuticals Corporation | $22.10 | 2022 | |
| Amgen INC. | $19.04 | 2021 | |
| Verity Pharmaceuticals INC. | $18.68 | 2022 | |
| Procept Biorobotics Corporation | $17.91 | 2024 | Aquabeam System |
| Rochester Medical Corporation | $15.84 | 2021 | |
| Endo USA, INC. | $15.60 | 2025 | Aveed, Xiaflex |
| Laborie Medical Technologies Corp. | $15.31 | 2024 | Optilume Bph Drug Coated Balloon Catheter |
| Allergan, INC. | $12.96 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gideon Richards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.